Alchemab Therapeutics
Dr. Levin joined RA Capital Management in 2015, is a Managing Director on the Investment Team and spearheads a drug discovery effort that has led to the formation of several new companies. Beginning in 2012, and prior to joining the Investment Manager, he was a Vice President at H.I.G. BioVentures. Previously he served as the Director of Pharmaceutical Sciences at the Clinton Health Access Initiative.
Dr. Levin holds a BSE in Mechanical Engineering from Princeton University, a PhD in Biomedical Engineering from the Massachusetts Institute of Technology, and an MD from Harvard Medical School.
This person is not in the org chart
This person is not in any offices
Alchemab Therapeutics
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development.